Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2023-2029

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2023-2029

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
LPI (LP Information)' newest research report, the “Glucagon Like Peptide-1 (GLP-1) Agonists Industry Forecast” looks at past sales and reviews total world Glucagon Like Peptide-1 (GLP-1) Agonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon Like Peptide-1 (GLP-1) Agonists sales for 2023 through 2029. With Glucagon Like Peptide-1 (GLP-1) Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon Like Peptide-1 (GLP-1) Agonists industry.
This Insight Report provides a comprehensive analysis of the global Glucagon Like Peptide-1 (GLP-1) Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon Like Peptide-1 (GLP-1) Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon Like Peptide-1 (GLP-1) Agonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon Like Peptide-1 (GLP-1) Agonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon Like Peptide-1 (GLP-1) Agonists.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is projected to grow from US$ 8624.4 million in 2022 to US$ 21310 million in 2029; it is expected to grow at a CAGR of 21310 from 2023 to 2029.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segmentation by application
Hospital
Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Glucagon Like Peptide-1 (GLP-1) Agonists market?
What factors are driving Glucagon Like Peptide-1 (GLP-1) Agonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon Like Peptide-1 (GLP-1) Agonists market opportunities vary by end market size?
How does Glucagon Like Peptide-1 (GLP-1) Agonists break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.